Immunogenicity of seven-valent pneumococcal conjugate vaccine administered at 6, 14 and 40 weeks of age in South African infants.
BACKGROUND: The high cost of pneumococcal conjugate vaccine (PCV) and local epidemiological factors contributed to evaluating different PCV dosing-schedules. This study evaluated the immunogenicity of seven-valent PCV (PCV7) administered at 6-weeks; 14-weeks and 9-months of age. METHODS: 250 healthy...
Main Authors: | Stephanie A Jones, Michelle Groome, Anthonet Koen, Nadia Van Niekerk, Poonam Sewraj, Locadiah Kuwanda, Alane Izu, Peter V Adrian, Shabir A Madhi |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3755982?pdf=render |
Similar Items
-
Immunogenicity of the seven valent conjugate in UK term and preterm infants pneumococcal vaccine
by: Moss, Samantha Jane
Published: (2008) -
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in Mexico
by: Maricruz Gutiérrez Brito, et al.
Published: (2013-06-01) -
Decrease in pneumococcal co-colonization following vaccination with the seven-valent pneumococcal conjugate vaccine.
by: Carina Valente, et al.
Published: (2012-01-01) -
Impact of seven-valent Pneumococcal Conjugate Vaccination (PCV7) on childhood pneumococcal diseases in the UK
by: El-Turki, A. A.
Published: (2013) -
Seven-Valent Pneumococcal Conjugate Vaccine and Nasopharyngeal Microbiota in Healthy Children
by: Giske Biesbroek, et al.
Published: (2014-02-01)